Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases

Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP/Maloney 3rd Floor, Philadelphia, PA 19104-4283, USA.
Acta Neuropathologica (Impact Factor: 9.78). 09/2007; 114(3):221-9. DOI: 10.1007/s00401-007-0261-2
Source: PubMed

ABSTRACT Here, we investigated if TAR-DNA-binding protein-43 (TDP-43), the disease protein in frontotemporal lobar degeneration and ubiquitin inclusions with or without motor neuron disease as well as amyotrophic lateral sclerosis, also formed inclusions in Lewy body (LB) disorders including Parkinson's disease (PD) without or with dementia (PDD), and dementia with LBs (DLB) alone or in association with Alzheimer's disease (AD). Immunohistochemical analyses of TDP-43 in clinically well characterized and pathologically confirmed cases of DLB + AD, PD and PDD demonstrated TDP-43 pathology in the following percentage of cases: DLB + AD = 25/80 (31.3%); PD = 5/69 (7.2%); PDD = 4/21 (19%), while DLB and normal controls exhibited no (0/10, 0%) and one cases (1/33, 3%) presenting TDP-43 pathology, respectively. Significant differences in the prevalence of TDP-43 lesions were noted between disease versus normal brains (P < 0.001) as well as demented versus non-demented brains (P < 0.001). Statistical analyses revealed a positive relationship between TDP-43 lesions and several clinical and pathological parameters in these disorders suggesting the TDP-43 pathology may have co-morbid effects in LB diseases. This study expands the concept of TDP-43 proteinopathies by implicating TDP-43 lesions in mechanisms of neurodegeneration in LB disorders.

Download full-text


Available from: Douglas Galasko, Jul 28, 2015
  • Source
    • "Previously a relatively little-studied protein, the stature of TDP- 43 has grown considerably due to description of mutations in the TARDBP gene in sporadic and familial cases of ALS and the discovery that TDP-43 is a major constituent of ubiquitin-positive inclusions in FTD and ALS (Neumann et al., 2006; Sreedharan et al., 2008). Subsequent demonstration that TDP-43 positive aggregates are found in numerous other neurodegenerative disorders including Parkinson's disease and AD have consequently raised the possibility that TDP-43 may be an intriguing therapeutic target outside of FTLD-TDP (Amador-Ortiz et al., 2007; Nakashima-Yasuda et al., 2007). TDP-43 is also one of a number of disease-related proteins with a known role in RNA metabolism (Polymenidou et al., 2011), a field that over the last decade has grown considerably in impact due to an increasing appreciation for its complexity and influence in multiple biological systems. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer's disease (AD). A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants in familial and sporadic forms of disease and the identification of TAR DNA binding protein of 43 kDa (TDP-43) as the defining constituent of inclusions in more than half of cases. In combination with an ever-expanding knowledge of the function and dysfunction of tau—a protein which is pathologically aggregated in the majority of the remaining cases—there exists a greater understanding of FTD than ever before. These advances may indicate potential approaches for the development of hypothetical therapeutics, but FTD remains highly complex and the roles of tau and TDP-43 in neurodegeneration are still wholly unclear. Here the challenges facing potential therapeutic strategies are discussed, which include sufficiently accurate disease diagnosis and sophisticated technology to deliver effective therapies.
    Frontiers in Aging Neuroscience 08/2014; 6. DOI:10.3389/fnagi.2014.00204 · 2.84 Impact Factor
  • Source
    • "Previous research has focused on assessing TDP- 43 pathogenesis in selected clinical populations, such as FTD groups. There has been some investigation in non-demented old individuals, with prevalence of solid neuronal TDP-43 inclusions reported to vary between 0 and 30% in clinic-based samples [18] [19] [20] [21] [22] [23] and to be 46% in a community-based sample [11]. One population-based (90+ Study) study has examined the prevalence in 108 individuals [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The significance of TDP-43 pathology in relation to aging and dementia in the population is unclear. Objective: We aimed to determine the prevalence of transactive response DNA-binding protein of 43 kDA (TDP-43) neuronal inclusions in a population-based sample, and associations with age group at death (≤90 and >90 years) and clinical dementia status prior to death. Further, we investigate associations between TDP-43 inclusions and other key dementia-related neuropathologies (plaques, tangles, and neuronal loss) within the hippocampus and entorhinal and temporal cortices. Methods: All brain donors within the Cambridge City over-75 s Cohort (CC75C), which is population-based and longitudinally tracked (n = 228), were included. Age at death ranged from 78 to 106 years. TDP-43 neuronal inclusions were assessed in the hippocampus, entorhinal cortex, and temporal cortex. These data were combined with existing clinical and neuropathological data. Results: TDP-43 neuronal inclusions were present in 27% of the sample, 36% of those with clinical dementia and 18% without dementia. Individuals who died later (>90 years) or with clinical dementia were more likely to show TDP-43 inclusions. Hippocampal and entorhinal TDP-43 inclusions were significantly associated with dementia severity and increasing age, taking into account other neuropathologies. TDP-43 neuronal inclusions appeared to co-localized with severe neuronal loss. Conclusion: Findings indicate that hippocampal and entorhinal TDP-43 inclusions are important substrates of late onset dementia which appear to co-localize with severe neuronal loss, but not with Alzheimer's disease markers of amyloid and tau. This broadens the accepted view of TDP-43 pathology in dementias.
    Journal of Alzheimer's disease: JAD 06/2014; 42(2). DOI:10.3233/JAD-132351 · 4.15 Impact Factor
  • Source
    • "Subsequent analysis of familial and sporadic cases of ALS revealed mutations in TDP-43 as a rare cause of the disease (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Yokoseki et al., 2008). TDP-43 pathology has now been identified in numerous neurodegenerative conditions associated with proteinaceous neuronal and nonneuronal inclusion formation, including Alzheimer's disease, Parkinson's disease, polyglutamine disorders suchasHuntington's disease, and Inclusion Body Myopathy (Amador-Ortiz et al., 2007; Guinto et al., 2007; Higashi et al., 2007; Nakashima-Yasuda et al., 2007; Neumann et al., 2007; Hu et al., 2008; Lin and Dickson, 2008; Schwab et al., 2008; Uryu et al., 2008; Weihl et al., 2008; Arai et al., 2009; Finch et al., 2009; Chanson et al., 2010; Lagier-Tourenne et al., 2010; Haraguchi et al., 2011; Pao et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The expression, processing, transport and activities of both coding and non-coding RNAs play critical roles in normal neuronal function and differentiation. Over the past decade, these same pathways have come under scrutiny as potential contributors to neurodegenerative disease. Here we focus broadly on the roles of RNA and RNA processing in neurodegeneration. We first discuss a set of "RNAopathies", where non-coding repeat expansions drive pathogenesis through a surprisingly diverse set of mechanisms. We next explore an emerging class of "RNA binding proteinopathies" where redistribution and aggregation of the RNA binding proteins TDP-43 or FUS contribute to a potentially broad range of neurodegenerative disorders. Lastly, we delve into the potential contributions of alterations in both short and long non-coding RNAs to neurodegenerative illness.
    Progress in Neurobiology 11/2011; 97(2):173-89. DOI:10.1016/j.pneurobio.2011.10.006 · 10.30 Impact Factor
Show more